Anxiety does not predict response to duloxetine in major depression: Results of a pooled analysis of individual patient data from 11 placebo-controlled trials

Depression and Anxiety

Volumn 27, Issue 1, 2010, Pages 12-18

  Nelson, J Craig ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ANXIETY; ARTICLE; DRUG EFFECT; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SOMATIZATION; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PERSONALITY INVENTORY; PROGNOSIS; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; THIOPHENES; TREATMENT OUTCOME;

EID: 75749145444     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20632     Document Type: Article

References (49)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105.
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163: 1905-1917.
3. Kupfer DJ, Spiker DG. Refractory depression: prediction on non-response by clinical indicators. J Clin Psychiatry 1981;42:307-312.
4. Roose SP, Glassman AH, Walsh BT, Woodring S. Tricyclic nonresponders, phenomenology and treatment. Am J Psychiatry 1986;143:345-348.
5. Nelson JC, Mazure CM, Jatlow PI. Characteristics of desipramine refractory depression. J Clin Psychiatry 1994;55:12-19.
6. Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001;13:18-27.
7. Tollefson GD, Holman SL, Sayler ME, Potvin JH. Fluoxetine, placebo, and tricyclics antidepressant in major depression with and without anxious features. J Clin Psychiatry 1994;55:50-59.
8. Joffe RT, Bagby M, Levitt A. Anxious and nonanxious depression. Am J Psychiatry 1993;150:1257-1258.
9. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family history study of anxious depression. Am J Psychiatry 1991;148: 1512-1517.
10. Fava M, Uebellacker LA, Alpert JE, et al. Major depressive subtypes and treatment response. Biol Psychiatry 1997;42:568-576.
11. Davidson JRT, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: it's relationship to anxiety symptoms. Depress Anxiety 2002;16:4-13.
12. Flint AJ, Rifat SL. Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatry 1997;5:107-115.
13. Dew MA, Reynolds CF, Houck PR, et al. Temporal profiles of the course of depression during treatment. Arch Gen Psychiatry 1997;54:1016-1024.
14. Grunhaus L, Harel Y, Krugler T, et al. Major depressive disorder and panic disorder: effects of comorbidity on treatment outcome with antidepressant medication. Clin Neuropharmacol 1988;11: 454-461.
15. Alexopoulos GS, Katz I, Bruce ML, et al. Remission in depressed geriatric primary care patients: a report from the PROSPECT study. Am J Psychiatry 2005;162:718-724.
16. Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry 2007;190:344-349.
17. Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. J Affect Disord 2003;77:247-254.
18. Fava M, Rush AJ, Alpert J, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-351.
19. Cleary P, Guy W. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1977;1:115-120.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
21. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004;34: 1299-1308.
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59: 22-33.
23. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
24. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231.
25. http://www.lillytrials.com/results-files/Cymbalta/Cymbalta-summary-3327b. pdf
26. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315.
27. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390.
28. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-470.
29. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Psychiatry 2006;21:367-378.
30. http://www.lillytrials.com/results-files/Cymbalta/Cymbalta-summary-4091a. pdf
31. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399.
32. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-909.
33. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53.
34. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007; 23:1303-1318.
35. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008;16:558-567.
36. Papakostas GI, Stahl SM, Krishen Alok, Fava M. Efficacy of bupropion and the selective reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression). Presented at the Annual Meeting of the American College of Neuropharmacology, Boca Raton FL, December 11, 2007.
37. Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59:123-127.
38. Shelton RC, Prakash A, Mallinckrodt CH, et al. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract 2007;61:1337-1348.
39. Nelson JC, Portera L, Leon AC. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biol Psychiatry 2005;57:1535-1542.
40. Nelson JC, Clary CM, Leon AC, Schneider LS. Symptoms of late life depression: frequency and change during treatment. Am J Geriatr Psychiatry 2005;13:520-526.
41. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatrica Scandinavica 1975;51:161-170.
42. Gibbons RD, Clark D, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 1993;27:259-273.
43. Maier W, Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985;18:114-115.
44. Evans KR, Sills T, DeBrota DJ, et al. An item response analysis of the Hamilton Depression Rating Scale using shared data from two pharmaceutical companies. J Psychiatr Res 2004;38: 275-284.
45. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167-174.
46. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008;25:182-189.
47. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
48. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid anxiety disorder. J Clin Psychiatry 2001;62:523-529.
49. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009;166:599-607.